Amorfix names Gundel as VP of R&D

Amorfix Life Sciences (TSX:AMF) has appointed 25-year drug development veteran Dr. Robert Gundel as vice president of research and development.

“Robert’s extensive record of new product advancement will be a great asset as we continue to discover, develop and commercialize novel diagnostic and therapeutic products based on our Epitope Protection and ProMIS technology platforms,” Dr. Neil Cashman, Amorfix’s chief scientific officer, said in a statement.

Prior to joining Amorfix, Dr. Gundel was the chief scientific officer at Heat Biologics, a clinical-stage company developing novel vaccine and monoclonal antibody technologies for the treatment of autoimmune diseases and cancers.

He was also vice-president and head of research at Elusys Therapeutics, where he directed all research and development programs in the areas of vaccines, anti-infectives and the anti-anthrax toxin monoclonal antibody, Anthem, being developed in collaboration with the National Institute of Allergy and Infectious Diseases, and the Department of Homeland Security for stockpiling as part of the U.S. biodefense program against potential terrorist attacks.